Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Neurocrine Biosciences (Nasdaq: NBIX) announced its participation in the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 8:00 a.m. ET. CEO Kyle Gano and VP of Investor Relations Todd Tushla will represent the company at the event.
The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for approximately one month after the event. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for various neurological conditions, including tardive dyskinesia, Huntington's disease chorea, and endometriosis.
Neurocrine Biosciences (Nasdaq: NBIX) ha annunciato la sua partecipazione alla 45陋 Conferenza Annuale sulla Crescita di Canaccord Genuity, che si terr脿 il 13 agosto 2025 alle 8:00 ET. Il CEO Kyle Gano e il VP delle Relazioni con gli Investitori Todd Tushla rappresenteranno l'azienda durante l'evento.
La presentazione sar脿 accessibile tramite webcast in diretta sul sito web delle relazioni con gli investitori della societ脿, con una replica disponibile per circa un mese dopo l'evento. Neurocrine Biosciences 猫 un'azienda biofarmaceutica specializzata in neuroscienze, con trattamenti approvati dalla FDA per diverse condizioni neurologiche, tra cui la discinesia tardiva, la corea di Huntington e l'endometriosi.
Neurocrine Biosciences (Nasdaq: NBIX) anunci贸 su participaci贸n en la 45陋 Conferencia Anual de Crecimiento de Canaccord Genuity, que se llevar谩 a cabo el 13 de agosto de 2025 a las 8:00 a.m. ET. El CEO Kyle Gano y el vicepresidente de Relaciones con Inversionistas, Todd Tushla, representar谩n a la empresa en el evento.
La presentaci贸n estar谩 disponible v铆a webcast en vivo en el sitio web de relaciones con inversionistas de la compa帽铆a, con una repetici贸n accesible durante aproximadamente un mes despu茅s del evento. Neurocrine Biosciences es una empresa biofarmac茅utica enfocada en neurociencias, con tratamientos aprobados por la FDA para diversas condiciones neurol贸gicas, incluyendo discinesia tard铆a, corea de Huntington y endometriosis.
Neurocrine Biosciences (雮橃姢雼�: NBIX)电� 2025雲� 8鞗� 13鞚� 鞓れ爠 8鞁�(霃欕秬鞁滉皠)鞐� 鞐措Μ电� Canaccord Genuity 鞝�45須� 鞐半 靹膘灔 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO 旃挫澕 瓴岇澊雲�(Kyle Gano)鞕� 韴瀽鞛� 甏�瓿� 攵�靷灔 韱犽摐 韯办姁霛�(Todd Tushla)臧� 鞚措矆 頄夓偓鞐愳劀 須岇偓毳� 雽�響滍暊 鞓堨爼鞛呺媹雼�.
氚滍憸电� 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 靸濎瓿勲 鞁滌箔頃� 靾� 鞛堨溂氅�, 頄夓偓 膦呺 頉� 鞎� 頃� 雼皠 雼れ嫓氤搓赴 靹滊箘鞀る弰 鞝滉车霅╇媹雼�. Neurocrine Biosciences电� FDA 鞀轨澑鞚� 氚涭潃 鞐煬 鞁犼步頃欖爜 歆堩櫂 旃橂鞝滊ゼ 氤挫湢頃� 鞁犼步瓿柬暀 欷戩嫭鞚� 氚旍澊鞓れ牅鞎� 須岇偓鞛呺媹雼�. 欤检殧 旃橂 雽�靸侅棎电� 歆�鞐办劚 鞖措彊鞛レ暊, 項岉寘韯� 氍措弰氤�, 鞛愱秮雮措歃� 霌膘澊 韽暔霅╇媹雼�.
Neurocrine Biosciences (Nasdaq : NBIX) a annonc茅 sa participation 脿 la 45e Conf茅rence Annuelle de Croissance de Canaccord Genuity, qui se tiendra le 13 ao没t 2025 脿 8h00 ET. Le PDG Kyle Gano et le vice-pr茅sident des relations investisseurs Todd Tushla repr茅senteront la soci茅t茅 lors de cet 茅v茅nement.
La pr茅sentation sera accessible via un webcast en direct sur le site des relations investisseurs de la soci茅t茅, avec une rediffusion disponible pendant environ un mois apr猫s l'茅v茅nement. Neurocrine Biosciences est une soci茅t茅 biopharmaceutique sp茅cialis茅e en neurosciences, disposant de traitements approuv茅s par la FDA pour diverses affections neurologiques, notamment la dyskin茅sie tardive, la chor茅e de Huntington et l'endom茅triose.
Neurocrine Biosciences (Nasdaq: NBIX) gab bekannt, dass das Unternehmen an der 45. j盲hrlichen Wachstumskonferenz von Canaccord Genuity am 13. August 2025 um 8:00 Uhr ET teilnehmen wird. CEO Kyle Gano und der Vizepr盲sident f眉r Investor Relations, Todd Tushla, werden das Unternehmen bei der Veranstaltung vertreten.
Die Pr盲sentation wird live 眉ber einen Webcast auf der Investor-Relations-Website des Unternehmens verf眉gbar sein, mit einer Wiederholung, die etwa einen Monat nach der Veranstaltung abrufbar ist. Neurocrine Biosciences ist ein biopharmazeutisches Unternehmen mit Schwerpunkt Neurowissenschaften und verf眉gt 眉ber von der FDA zugelassene Behandlungen f眉r verschiedene neurologische Erkrankungen, darunter tardive Dyskinesie, Huntington-Chorea und Endometriose.
- None.
- None.
The live webcast can be accessed on Neurocrine Biosciences' website under Investors at . A replay of the webcast will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit聽, and follow the company on , and .
(*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:
SOURCE Neurocrine Biosciences, Inc.
FAQ
When is Neurocrine Biosciences (NBIX) presenting at the Canaccord Genuity Conference?
Who will be presenting for Neurocrine Biosciences at the Canaccord conference?
How can investors access Neurocrine Biosciences' Canaccord conference presentation?
What are Neurocrine Biosciences' (NBIX) main FDA-approved treatments?
